Table 1

Baseline demographic and population characteristics

StudyRecruitment periodNAge (years)
(mean±SD)
MaleLVEFLog EuroSCORE
(mean±SD)
STS score
(mean±SD)
Type of valveAccess routeEchocardiographyMean/median follow-upSVD (%)Type of SVD
Rodés-Cabau 20122005–200933981.0±8.044.8%55%NR9.8±6.4Cribier-Edwards 61 (18%), Edwards-SAPIEN 275 (80%), Edwards-SAPIEN-XT 7 (2%)Transfemoral 162 (48%), transapical 177 (52%)Baseline, discharge, 1 year and annually thereafter4 years0
Toggweiler 20132005–20078883.0±7.053%60%NR9.0 (6.1–12.8)*Edwards-SAPIEN 39 (44%), CoreValve 49 (56%)Transfemoral 64 (73%), transapical 24 (27%)Baseline, discharge, 1 month, and annually5 years3.4One regurgitation,
one stenosis,
one mixed
Gotzmann 20142008–201015079.0±6.050%53%23.0%±17.0%NRCoreValve (100%)Transfemoral 145 (97%), transaxillary (3%)Baseline, 5 days post-implant, 1 year, and annually thereafter2.2 years2Five regurgitation
Kovac 20162006–200812682.4±6.442.9%NR23.4%±13.8%NRCoreValve (100%)Retrograde (100%)Baseline, discharge, 1 month, 6 months, 1 year and annually thereafter2.8 years0
Bouleti 20152006–200912281.5±8.456.1%50.1%21.8%±12.4%7.1±4.7Edwards-SAPIEN 112 (90.3%), CoreValve 12 (9.7%)Transfemoral 84 (68%), transapical 37 (30%), other 2 (2%)Echocardiographic follow-up was left to the discretion of the patients’ cardiologists3.6 years4.1Two regurgitation,
three stenosis
Barbanti 20152007–200935381.5±6.344.5%50.6%21.5% (15-31)*9.5±10.0CoreValve (100%)Transfemoral 43 (86%), trans-subclavian 2 (4%), transapical 5 (10%)Echocardiographic follow-up was performed according to each centre’s clinical practice3.9 years4.2Two regurgitation, 11 stenosis
Gulino 20162007–201012581.1±4.740%50.6%23.7%±14%6.1±3.5CoreValve 100%Transfemoral 122 (98%), transapical 3 (2%)Baseline, discharge,
1 month, 1 year and annually thereafter
4.4 years5.6Three regurgitation,
four stenosis
Sawaya 20162004–200841082.3±5.636.6%NR28.4%±13.3%NREdwards-SAPIEN 388 (94.6%), CoreValve 22 (5.4%)Combined transfemoral and transapicalBaseline, post-implant, discharge, 1 year and annually thereafter5 years0
Papadopoulos 20162005–201531279.8±5.842%51%23.9%±17.2%9.8±8.6Cribier-Edwards, Edwards-SAPIEN, Edwards-SAPIEN-XT,
Edwards Sapien3
Transfemoral 234 (75%), transapical 78 (25%)Discharge, 6 months,
1 year and annually thereafter
4.1 years0
D’Onofrio 20162007–201333880.3±6.753.6%55%17.3%±3.0%NREdwards-SAPIEN 255 (75.4%), CoreValve 83 (24.6%)Transfemoral 233 (69%), transapical 105 (31%)Baseline, discharge, between 2 and 6 months and 12 months thereafter1.8 years0
Ruparelia 20162007–201582982.6±8.241.6%NR22.7%±16.8%8.9±9.3NRTransfemoral 703 (85%), other 126 (15%)Unclear5 years0
Del Trigo 20162007–2014152181.0±7.048%57.3%17.8%±12.5%NREdwards-SAPIEN 738 (48.5%), CoreValve 756 (49.7%)Transfemoral 1221 (80%), transapical or transaortic 261 (17%)Baseline, discharge, 6 to 12 months and yearly thereafter4 years4.5Not reported
Gilard 20162010–2012420182.5±7.150.5%53.1%21.6%±14.2%NREdwards-SAPIEN 2774 (66%), CoreValve 1413 (34%)Transfemoral 3064 (73%), transapical 735 (17%), subclavian 242 (6%)30 days, 6 months, 1 year and annually thereafter3.8 years0
  • *Median (25th–75th percentile). NR, not reported.